Solid tumors contain abnormal and heterotypic cells that communicate through tight and gap junctions. In contrast with liquid tumors, as the cells multiply, they form a “mass” called a solid tumor and usually do not contain pockets of fluid, pus, air, or other substances. Solid tumors can be either non-cancerous (benign), pre-malignant (cells that have the potential to become malignant), or malignant (cancerous).
Solid tumors represent approximatively 90% of adult human cancers. They can develop in many parts of the human body, including the breast, lung, prostate, colon, melanoma, bladder, and kidney.
Examples of localized solid tumors:
In early stages of clinical trials is “solid tumours” is often used as a catch-all when testing new drugs and combinations so there are no antibodies approved for this large demographic.
Antibodies that are in clinical trials for the treatment of solid tumors are:
Antibodies that are in clinical trials for combined treatment of non-small cell lung cancer are:
- AB154 and Zimberelimab
- ASP8374 and Pembrolizumab
- BGB-A1217 and Tislelizumab
- BI-754111 and BI-754091
- BMS-986207 and Nivolumab
- BMS-986207 and Nivolumab and Ipilimumab
- Eigliimab and Nivolumab
- MK-1308 and Pembrolizumab
- Selicrelumab and Atezolizumab
- TSR-033 and dostarlimab or bevacizumab
- Utomilumab and mogamulizumab
- Vibostolimab and Pembrolizumab
- Zimberelimab and domvanalimab
- SHR1702 and Camrelizumab
- LY3321367 and LY3300054
- BMS986258 and Nivolumab
- HMBD-002 and Pembrolizumab
- MGD009 and Retifanlimab
Click here to see the raw data and add any missing antibody drugs. If you want to manipulate the data please copy the spreadsheet first.